Dr. Sharon Orrange - October 06, 2015
More than 29 million Americans have diabetes. That’s more than 10% of the US—and that number continues to rise. More than 1.7 million adults were diagnosed with diabetes in 2012 alone.
Fortunately, several new medications for diabetes have recently been approved—Toujeo (a new insulin product), Synjardy (a new combination of empagliflozin/metformin) and others. These new drugs provide several benefits such as fewer side effects or foolproof self-dosing with an insulin pen. See More
The GoodRx Pharmacist - September 04, 2015
On August 28, 2015, the FDA issued a safety warning for a newer type of type 2 diabetes medication known as DPP-4 inhibitors or gliptins.
There have been reports that these medications can cause severe and possibly disabling joint pain.
Which medications contain gliptins (DPP-4 inhibitors)?
- Januvia (sitagliptin)
- Onglyza (saxagliptin)
- Tradjenta (linagliptin)
- Nesina (alogliptin)
- Janumet and Janumet XR (metformin and sitagliptin)
- Kombiglyze XR (saxagliptin and metformin)
- Glyxambi (empagliflozin and linagliptin)
- Jentadueto (metformin and linagliptin)
- Kazano (alogliptin and metformin)
- Oseni (alogliptin and pioglitazone)
Why was a FDA safety warning issued for gliptin medications?
The FDA issued the warning due to continued reports of severe joint pain associated with the use of gliptin medications. See More
Dr. Sharon Orrange - November 04, 2014
The newest of the injectable diabetes medications which also helped diabetics lose weight is Trulicity, just approved in September 2014. Given that Trulicity has a low incidence of hypoglycemia and mild gastrointestinal side effects it will become a good option for type II diabetics.
Dr. Sharon Orrange - January 02, 2014
2013 was a year for many new treatments for type II diabetes. For healthcare workers and patients it’s hard to keep up with the newer medications for the treatment of adult onset diabetes, and treating diabetes is an art and not a “one-size fits all” algorithm. For our folks struggling with type II diabetes the outlook just got brighter because of a class of drugs known as incretin based drugs. Here is the down-low on these medications. See More
The GoodRx Pharmacist - July 25, 2013
Invokana (canaglifozin) is now readily available at most pharmacies after receiving approval for the treatment of type 2 diabetes earlier this year. Here’s what you need to know.
What is Invokana?
Type 2 diabetes leads to elevated levels of glucose in the blood, because of the inability of your body either to make enough insulin or because your cells cannot use it properly. Invokana is a novel drug that works by blocking glucose from being reabsorbed by the kidney. See More
Dr. Sharon Orrange - February 02, 2012
No, it’s not insulin. New injections for diabetes may change the way we manage adult-onset diabetes. Approval of a new once-a-week injection called Bydureon is an exciting new option for blood sugar control. This new class of injectables may be popular for several reasons, not the least of which is they also result in weight loss. Yippee!
Though it sounds straight out of outer space, these drugs are called incretin mimetics, meaning they mimic the incretin hormones that tell your body to release insulin after eating. See More
Dr. Sharon Orrange - January 11, 2012
A new combination pill targeted at diabetes and cholesterol is hitting the market and you will be hearing about it. Juvisync is a combination medication that contains two previously approved medicines: the generic cholesterol medication simvastatin, and Januvia (sitagliptin) a diabetes medication.
What are the upsides of Juvisync?
1) First off, you kill two birds with one stone and treat diabetes and cholesterol in one pill. See More
Dr. Sharon Orrange - December 09, 2011
What are the most dangerous medications? Results from a recent study highlight four drugs that are responsible for a shocking number of negative effects. Data from 2007 – 2009 shows that these four drugs were involved in more than two-thirds of the hospitalizations of older patients for harmful drug reactions and incidents.
Researchers looked at emergency hospitalizations of adults aged 65 years and older that were attributed to the use of a drug, or a drug-specific adverse effect. See More